Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Bavarian Nordic A/S (BAVA.CO)
Hellerup, DK
Hellerup, Denmark-based Bavarian Nordic A/S, founded in 1992, specializes in the research, production, and global distribution of vital, life-saving vaccines. The company's commercialized offerings include non-replicating vaccines for smallpox and monkeypox, marketed as IMVAMUNE, IMVANEX, and JYNNEOS. Additionally, their portfolio features Rabipur/RabAvert for rabies prevention, Encepur for tick-borne encephalitis, and MVABEA, an Ebola vaccine. Bavarian Nordic also maintains a robust pipeline of investigational treatments. This includes MVA-BN (freeze-dried), which has successfully completed Phase III clinical trials for smallpox; MVA-BN RSV, currently in Phase III development for respiratory syncytial virus; ABNCoV2, which completed Phase II trials targeting SARS-CoV-2; and TAEK-VAC, presently in Phase I/II trials for advanced HER2 and brachyury-expressing cancers. The firm engages in key partnerships, notably a license and collaboration agreement with AdaptVac, and licensing agreements with both the National Cancer Institute and the Public Health Service. Bavarian Nordic operates across a wide international footprint, with a presence in countries such as the United States, Germany, Belgium, France, Canada, the United Kingdom, Hong Kong, Saudi Arabia, Australia, Switzerland, and numerous other global markets.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.09% | +0.27% | -5.85% | -1.93% | +6.75% | -2.33% | +17.50% | -10.46% | -30.59% | -22.99% | +110.89% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 3 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+8.0% ★ Q1'26: -21.4% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+39.8% ★ Q1'26: -91.9% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+18.3% Q1'26: -74.0% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+14.9% ★ Q1'26: -0.6% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+7.3% ★ Q1'26: -0.2% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%-0.1% ★ Q1'26: -4.8% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.08× ★ Q1'26: 0.21× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 4 Rev. Ana. 3 EPS Ana. |
Dec 2028 3 Rev. Ana. 3 EPS Ana. |
Dec 2029 2 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.02B
est: 1.02B (-0.3%)
|
1.01B
est: 1.04B (-3.2%)
|
1.37B
est: 1.30B (+5.8%)
|
500.62M
est: 509.48M (-1.7%)
|
662.49M
est: 599.95M (+10.4%)
|
1.85B
est: 1.90B (-2.5%)
|
1.90B
est: 1.95B (-2.7%)
|
3.15B
est: 3.10B (+1.6%)
|
7.06B
est: 6.08B (+16.1%)
|
5.72B
est: 5.58B (+2.4%)
|
6.17B
est: 6.10B (+1.2%)
|
5.38B
5.22B – 5.83B
-11.7% YoY
|
5.49B
5.17B – 5.73B
+2.0% YoY
|
5.92B
5.78B – 6.07B
+7.9% YoY
|
6.37B
6.09B – 6.78B
+7.6% YoY
|
6.49B
6.20B – 6.90B
+1.8% YoY
|
| EBITDA |
127.69M
est: 201.49M (-36.6%)
|
87.31M
est: 204.64M (-57.3%)
|
345.09M
est: 254.92M (+35.4%)
|
-300.47M
est: 100.28M (-399.6%)
|
-269.21M
est: 118.09M (-328.0%)
|
657.91M
est: 373.80M (+76.0%)
|
35.80M
est: 384.00M (-90.7%)
|
84.28M
est: 610.66M (-86.2%)
|
2.05B
est: 1.09B (+88.7%)
|
1.67B
est: 998.31M (+67.7%)
|
1.64B
est: 1.09B (+50.0%)
|
962.29M
933.09M – 1.04B
-11.7% YoY
|
981.58M
924.26M – 1.02B
+2.0% YoY
|
1.06B
1.03B – 1.08B
+7.9% YoY
|
1.14B
1.09B – 1.21B
+7.6% YoY
|
1.16B
1.11B – 1.23B
+1.8% YoY
|
| EBIT |
84.16M
est: 57.26M (+47.0%)
|
43.23M
est: 58.16M (-25.7%)
|
353.19M
est: 72.45M (+387.5%)
|
-342.10M
est: 28.50M (-1,300.4%)
|
-326.26M
est: 33.56M (-1,072.1%)
|
313.83M
est: 106.23M (+195.4%)
|
-302.37M
est: 109.13M (-377.1%)
|
-211.92M
est: 173.55M (-222.1%)
|
1.50B
est: 315.68M (+374.5%)
|
1.05B
est: 289.77M (+262.1%)
|
920.78M
est: 316.33M (+191.1%)
|
279.32M
270.84M – 302.47M
-11.7% YoY
|
284.92M
268.28M – 297.41M
+2.0% YoY
|
307.44M
300.00M – 314.88M
+7.9% YoY
|
330.79M
316.01M – 351.61M
+7.6% YoY
|
336.84M
321.79M – 358.04M
+1.8% YoY
|
| Net Income |
59.43M
est: 131.45M (-54.8%)
|
30.60M
est: 85.39M (-64.2%)
|
181.34M
est: 585.95M (-69.1%)
|
-361.93M
est: -675.40M (+46.4%)
|
-346.78M
est: -652.59M (+46.9%)
|
277.52M
est: 705.84M (-60.7%)
|
-464.78M
est: -375.63M (-23.7%)
|
-347.38M
est: -253.98M (-36.8%)
|
1.48B
est: 707.42M (+108.5%)
|
987.98M
est: 915.87M (+7.9%)
|
1.38B
est: 1.38B (+0.0%)
|
788.00M
556.45M – 968.02M
-42.7% YoY
|
808.68M
734.47M – 1.02B
+2.6% YoY
|
1.06B
922.36M – 1.39B
+30.7% YoY
|
928.53M
874.59M – 1.00B
-12.2% YoY
|
—
— – —
-100.0% YoY
|
| SGA |
217.06M
est: 214.58M (+1.2%)
|
212.77M
est: 217.93M (-2.4%)
|
207.94M
est: 271.47M (-23.4%)
|
213.68M
est: 106.80M (+100.1%)
|
226.89M
est: 125.76M (+80.4%)
|
563.93M
est: 398.08M (+41.7%)
|
484.70M
est: 408.95M (+18.5%)
|
588.96M
est: 650.33M (-9.4%)
|
872.43M
est: 1.15B (-23.9%)
|
1.02B
est: 1.05B (-3.5%)
|
1.23B
est: 1.15B (+7.0%)
|
1.02B
984.23M – 1.10B
-11.7% YoY
|
1.04B
974.91M – 1.08B
+2.0% YoY
|
1.12B
1.09B – 1.14B
+7.9% YoY
|
1.20B
1.15B – 1.28B
+7.6% YoY
|
1.22B
1.17B – 1.30B
+1.8% YoY
|
| EPS |
1.66
est: 1.68 (-1.4%)
|
0.79
est: 1.09 (-27.7%)
|
4.51
est: 7.50 (-39.9%)
|
-8.88
est: -8.65 (-2.7%)
|
-8.50
est: -8.36 (-1.7%)
|
5.13
est: 9.04 (-43.2%)
|
-7.37
est: -4.81 (-53.2%)
|
-4.93
est: -3.24 (-52.3%)
|
19.23
est: 9.07 (+112.0%)
|
12.61
est: 11.60 (+8.7%)
|
17.63
est: 21.81 (-19.2%)
|
9.78
7.13 – 12.41
-55.2% YoY
|
10.92
9.41 – 13.06
+11.6% YoY
|
14.40
11.82 – 17.84
+31.9% YoY
|
11.90
11.21 – 12.87
-17.4% YoY
|
—
— – —
-100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-11 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 4/5 | 3/5 | 4/5 |
| 2026-05-08 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-07 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-06 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-05-05 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-05-04 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-30 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-29 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-28 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-27 | A+ | 5/5 | 5/5 | 4/5 | 5/5 | 3/5 | 4/5 | 4/5 |
| 2026-04-24 | A+ | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 4/5 |
| 2026-04-23 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-22 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-21 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-20 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-17 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
| 2026-04-16 | A | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 3/5 | 4/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares MSCI Denmark ETF EDEN | 0.84% | 1.73M | 0.53% |
| 2 | Vident International Equity Strategy ETF VIDI | 0.41% | 1.60M | 0.61% |
| 3 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.31% | 972.6K | 0.31% |
| 4 | iShares Healthcare Innovation UCITS ETF HEAL.L | 0.25% | 2.81M | 0.40% |
| 5 | Dimensional - International Small Cap Value ETF DISV | 0.16% | 7.40M | 0.42% |
| 6 | State Street SPDR MSCI Europe Small Cap Value Weighted UCITS ETF EUR Acc ZPRX.DE | 0.15% | 1.17M | 0.30% |
| 7 | iShares MSCI Europe Small-Cap ETF IEUS | 0.14% | 253.0K | 0.41% |
| 8 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.14% | 4.88M | 0.30% |
| 9 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Acc CEM.PA | 0.14% | 469.4K | 0.23% |
| 10 | Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF Dist X026.DE | 0.14% | 469.4K | 0.23% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Paul John Chaplin | Chief Executive Officer & President | 20M | — |
| Henrik Juuel | Chief Financial Officer & Executive Vice President | 12M | male |
| Jean-Christophe May | Executive Vice President & Chief Commercial Officer | — | male |
| Nicole Seroff | Vice President Corporate Communications | — | female |
| Rolf Sass Sørensen | Vice President of Investor Relations | — | male |
| Russell Thirsk | Executive Vice President & Chief Operating Officer | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for BAVA.CO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
